June 26, 2026
Alcresta Therapeutics Announces Preclinical Data Evaluating RELiZORBneo Cartridge Use in Neonatal Murine Model of Necrotizing Enterocolitis
B Preclinical data published in PLOS ONE highlight potential safety benefit of RELiZORBneo WALTHAM, Mass., May 1, 2026 /PRNewswire/ — Alcresta Therapeutics, Inc., a leading commercial-stage…
